Grant: Project Grant
University of Toronto
$286,876.00
Self, Memory, and Brain Aging in Transfeminine Persons
EF 2023-24
Résumé
Dementia refers to a collection of age-related diseases, including Alzheimer's Disease, in which memory, concentration, and other brain-based skills decline, usually in old age. Among cisgender people (i.e., people whose gender identity aligns with the sex they were assigned at birth), more women than men experience dementia at a given age. Possible explanations for this include; the differences between men and women in sex-related hormones; sex chromosomes; and gender-related social factors such as caring responsibilities. Transfeminine people (i.e., people who were assigned male at birth but whose gender identity is not male) are often prescribed a sex-related hormone, 17-beta-estradiol (E2). E2 causes physical changes that help transfeminine people see themselves, and be seen by others, in a way that is aligned with their gender identity. This treatment is known to improve mental health and wellbeing. E2 is known to be involved in regulating brain development in all sexes, and in cis women, changes to behaviour and brain with the decline of E2 at menopause contributing to their greater risk of dementia. However, we do not know what effect E2 treatment has on the dementia risk of transfeminine people. This project expands an existing study where we interview transfeminine people about experiences with E2, test their cognition, and scan their brains. We propose to ask more questions, and take biological samples. We aim to explore gender-related social factors transfeminine people experience, and examine how stress and E2 treatment affect biological processes that contribute to dementia and aging. The knowledge gained from this study will contribute to the growing field of gender-affirming care and treatment, and to our understanding of the roles of sex and stress in dementia risk, which will positively impact the care experiences and outcome for transfeminine people and people at risk of dementia across Canada and beyond.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
501483
Name
Einstein Gillian
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Biomedical
Prcname2
Gender, Sex & Health
Projecttitle
Self, Memory, and Brain Aging in Transfeminine Persons
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$286,876
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
17-Beta-Estradiol; Aging; Dementia; Gender Affirming Estradiol Therapy (Gaet); Intertwined Effects Of Sex And Gender; Memory; Senescence, Inflammation And Immunity; Sexual Minority Stress; Transfeminine; Very Mixed Methods
Abstract
Dementia refers to a collection of age-related diseases, including Alzheimer's Disease, in which memory, concentration, and other brain-based skills decline, usually in old age. Among cisgender people (i.e., people whose gender identity aligns with the sex they were assigned at birth), more women than men experience dementia at a given age. Possible explanations for this include; the differences between men and women in sex-related hormones; sex chromosomes; and gender-related social factors such as caring responsibilities. Transfeminine people (i.e., people who were assigned male at birth but whose gender identity is not male) are often prescribed a sex-related hormone, 17-beta-estradiol (E2). E2 causes physical changes that help transfeminine people see themselves, and be seen by others, in a way that is aligned with their gender identity. This treatment is known to improve mental health and wellbeing. E2 is known to be involved in regulating brain development in all sexes, and in cis women, changes to behaviour and brain with the decline of E2 at menopause contributing to their greater risk of dementia. However, we do not know what effect E2 treatment has on the dementia risk of transfeminine people. This project expands an existing study where we interview transfeminine people about experiences with E2, test their cognition, and scan their brains. We propose to ask more questions, and take biological samples. We aim to explore gender-related social factors transfeminine people experience, and examine how stress and E2 treatment affect biological processes that contribute to dementia and aging. The knowledge gained from this study will contribute to the growing field of gender-affirming care and treatment, and to our understanding of the roles of sex and stress in dementia risk, which will positively impact the care experiences and outcome for transfeminine people and people at risk of dementia across Canada and beyond.
Competitiondate
202403
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Einstein, Gillian
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $286,876~ $0~